NCT07215962

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

Real-World Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Pd-L1 <1% in the Florida Cancer Specialists & Research Institute Database

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 300 (estimated)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy

Conditions

• Non-small Cell Lung Cancer (NSCLC)

Interventions

Type	Name	Description
BIOLOGICAL	Nivolumab + ipilimumab	According to the product label
BIOLOGICAL	Nivolumab + ipilimumab + platinum-based chemotherapy	According to the product label
BIOLOGICAL	Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy	According to the product label
BIOLOGICAL	Other dual-immuno-oncology therapy with chemotherapy	According to the product label

Timeline

• Start date: 2024-11-22
• Primary completion: 2025-07-01
• Completion: 2026-03-01
• First posted: 2025-10-14
• Last updated: 2025-10-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study